Jiangsu Hengrui Pharmaceuticals(600276.SH): The injectable SHR-A2009 and adalimumab injection have obtained approval for clinical trials of drugs.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd., have recently received approval from the National Medical Products Administration for the clinical trial of injection SHR-A2009 and Atezolizumab injection. Injection SHR-A2009 is an antibody-drug conjugate targeting HER3, which specifically binds to HER3 on the surface of tumor cells, and is then internalized into cells and transported to lysosomes, where it releases free toxins to kill tumor cells. There are currently no similar drugs approved for market worldwide. As of now, the total research and development investment in the SHR-A2009 injection project is approximately 114.6 million yuan. Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody developed independently by the company. It blocks the PD-1/PD-L1 pathway that induces immune tolerance in tumors by specifically binding to the PD-L1 molecule, reactivating the immune system's anti-tumor activity and achieving the goal of treating tumors. Similar products such as Atezolizumab (brand name: Tecentriq), Avelumab (brand name: Bavencio), and Durvalumab (brand name: Imfinzi) have been approved for sale in the United States, with Atezolizumab and Durvalumab also approved for sale in China. Domestic products such as Envolitab (Kangning Jie/Silicon Therapeutics), Sugenlitab (Kistone Pharmaceuticals), and Bemlosu Bai (Zhengda Tiandi Pharmaceuticals) have been approved for sale. The company's Atezolizumab injection (brand name: Eleri) was approved for sale in March 2023 for first-line treatment in extensive stage small cell lung cancer patients when combined with carboplatin and etoposide. In 2023, global sales of Atezolizumab, Avelumab, and Durvalumab totaled approximately 8.985 billion US dollars. As of now, the total research and development investment in the Atezolizumab injection project is approximately 784.71 million yuan.